Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Eurozone AlphaDEX UCITS ETF 09.01.2026 FEUZ IE00B8X9NY41 1,105,638.00 EUR 65,528,310.79 59.267  ...

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today reported preliminary, unaudited financial results for the fourth quarter and full year 2025. Preliminary Fourth Quarter 2025 Financial Results Revenue of approximately $108 million, an increase of 25% ye...

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced preliminary fourth quarter and full-year 2025 revenue and also announced a transition of the Company’s Chief Financial Officer....

JACKSONVILLE, Fla.--(BUSINESS WIRE)--FIS® (NYSE: FIS), a global leader in financial technology, today announced the launch of its first offering to enable agentic commerce on the heels of announcing the close of the acquisition of its FIS Total Issuing™ Solutions portfolio. FIS’ new agentic commerce offering is the first to enable banks to safely and securely conduct commerce with AI agents and card networks. In agentic commerce transactions, AI functions as a personal digital assistant that ca...

MENTONE, Texas--(BUSINESS WIRE)--Independence Power Holdings (OTC: ITXP) announces its transition to a public-reporting company following a completed business combination....

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today provided a business update and announced strategic priorities for 2026, highlighting recent progress for its two lead programs, upcoming clinical milestones, and a strong financial position supporting execution through key value-inflection points. “We continue...

NEW YORK--(BUSINESS WIRE)--MindMed Announces Rebrand to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026...

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (NASDAQ:HYFT) (« MindWalk » ou la « société »), une société d'IA bio-native spécialisée dans la recherche et les technologies thérapeutiques, annonce aujourd’hui une avancée dans son programme universel de lutte contre la grippe à la suite de l’identification d’une contrainte fonctionnelle révolutionnaire qui persiste à travers les virus de la grippe malgré une évolution continue. En utilisant sa technologie brevetée HYFT® Deep Data, MindW...

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer (“CEO”), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and ef...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company's 2025 achievements and provided additional updates on key milestones expected in 2026. Ionis will provide a business update at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13 at 8:15am PT; the presentation is available today on the Ionis website here. “2025 was a defining year for Ionis, as we successfully executed our first two independent launches...